GAD Treatment Market to Reach $4.26 B by 2033, J&J Among Key Players
Johnson & Johnson is listed among active biotech firms targeting generalized anxiety disorder in a market projected to expand from $1.8 billion in 2023 to $4.26 billion by 2033. Innovations in digital mental health tools and novel therapies could boost J&J’s mental health segment growth.
1. Inclusion in GAD Treatment Market
Johnson & Johnson is named among active companies in the generalized anxiety disorder therapies space, competing with firms such as Helus Pharma and Acadia Healthcare in developing both pharmacologic treatments and digital health solutions.
2. Market Growth Drivers and Implications
Industry projections anticipate the GAD treatment market will grow from about $1.8 billion in 2023 to $4.26 billion by 2033, driven by telehealth services, cognitive-behavioral tools, and new medication platforms, potentially enhancing J&J’s mental health revenues.